ArticleBreast cancer research : BCR2020

Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer.

Sunil Pancholi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.